San Diego, California, United States, November 20, 2026
Erasca, Inc., a clinical-stage precision oncology company, has announced encouraging updated Phase 1 clinical results for ERAS-0015, its investigational oral pan-RAS molecular glue designed to target RAS-driven cancers. The updated findings from the ongoing AURORAS-1 clinical trial demonstrated confirmed anti-tumour responses across several KRAS-mutant solid tumour types, including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and biliary tract cancer (BTC). At the 32 mg once-daily dose, ERAS-0015 achieved a confirmed objective response rate (ORR) of 44% in patients with previously treated KRAS G12X pancreatic cancer. The response rate increased to 69% among patients with KRAS G12D or G12V mutations in the same treatment setting. The company also reported encouraging findings in previously treated KRAS-mutant NSCLC and biliary tract cancer, alongside generally favourable tolerability at pharmacologically active doses. These results strengthen Erasca’s plans to advance ERAS-0015 into potentially registration-enabling clinical studies. The company intends to initiate a study in second-line or later RAS-mutant NSCLC during the first half of 2027 and accelerate its planned Phase 3 study in first-line pancreatic cancer to the same period.
ERAS-0015 Demonstrates Anti-Tumour Activity Across Multiple Cancers
The updated results from the AURORAS-1 Phase 1 trial evaluated ERAS-0015 as monotherapy in patients with advanced RAS-mutant solid tumours. At the 32 mg once-daily dose, the candidate demonstrated a 44% confirmed ORR among 25 patients with second-line or later KRAS G12X pancreatic ductal adenocarcinoma. Notably, 84% of these participants had received three or more previous lines of treatment, indicating a heavily pretreated population. Among the 13 patients with KRAS G12D or G12V mutations, the confirmed ORR reached 69%, including 63% in the KRAS G12D subgroup and 80% in the KRAS G12V subgroup. These mutation types are particularly relevant because they account for a substantial proportion of pancreatic cancer cases. In previously treated KRAS G12X NSCLC following immune checkpoint inhibitor and platinum-based chemotherapy, the company reported a confirmed ORR of 60% among five patients receiving 32 mg once daily. Across the pharmacologically active dose range of 16–32 mg, the confirmed ORR was 58% among 12 patients. In biliary tract cancer, the 32 mg dose produced a reported confirmed ORR of 75% among four patients. Although these response rates are encouraging, the small subgroup sizes and early Phase 1 design mean that larger controlled studies are needed to establish the magnitude and durability of clinical benefit.
Molecular Glue Approach Targets RAS Signalling
ERAS-0015 is an investigational oral pan-RAS molecular glue designed to inhibit RAS signalling across multiple RAS variants. RAS proteins play important roles in regulating cell growth, division and survival. Mutations affecting RAS signalling can lead to uncontrolled cellular proliferation and contribute to several aggressive cancers, including pancreatic, lung and colorectal cancers. Unlike therapies designed to inhibit only one specific mutant form of RAS, ERAS-0015 is being developed to target a broader range of RAS variants, including RAS wild-type proteins. Erasca believes this broader mechanism may help address resistance mechanisms associated with mutant-selective inhibitors. The company also reported early combination findings involving ERAS-0015 with gemcitabine plus nab-paclitaxel, pembrolizumab and panitumumab. These combinations were generally well tolerated in the dose-escalation cohorts reported. Multiple responses were observed in some combination settings, including KRAS-mutant colorectal cancer with panitumumab. However, combination efficacy data remain preliminary, and further dose exploration is ongoing. Erasca expects additional combination-development updates during 2027.
Safety Findings and Next Clinical Development Milestones
At pharmacologically active doses of 16–32 mg once daily, ERAS-0015 was generally well tolerated, with mostly low-grade treatment-related adverse events and low rates of dose interruptions, reductions and discontinuations. At 32 mg, treatment-related adverse events led to dose interruptions in 13% of patients and dose reductions in 16.7%, with no treatment discontinuations reported at that dose. However, the company also disclosed an important serious safety event from its earlier programme: one patient experienced pneumonitis that progressed to a fatal outcome after supportive care was withdrawn at the patient’s request. This event highlights the need for continued safety monitoring as clinical development advances. Erasca is also developing ERAS-4001, an investigational pan-KRAS inhibitor that has shown preliminary Phase 1 activity and favourable tolerability. The company plans to initiate a combination dose-escalation study evaluating ERAS-0015 with ERAS-4001 in 2027. For ERAS-0015, planned milestones include a potentially registration-enabling second-line or later NSCLC study and a Phase 3 first-line pancreatic cancer study in the first half of 2027. A separate Phase 3 first-line RAS-mutant NSCLC study is expected between the second half of 2027 and the first half of 2028. Both ERAS-0015 and ERAS-4001 remain investigational medicines, and their safety and efficacy will require confirmation in larger clinical trials.
Source: Erasca press release



